OncoMethylome Expands MGMT Methylation Agreement with Schering-Plough

Oct 25, 2006

NEW YORK (GenomeWeb News) - OncoMethylome Sciences said yesterday that it has extended an existing agreement with Schering-Plough to provide methylation testing in clinical trials focused on brain cancer and other cancers.

The agreement applies to OncoMethylome’s methylation assay for the MGMT biomarker, which has been shown to be methylated in a number of cancer types.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Marks Left on the Genome

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

Cost and Coverage of Gene Therapies

The Wall Street Journal looks into the cost of new gene therapies.

Mosquito Population Crash

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

This Week in PNAS

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.

Main menu